Project Grant R01DK147991
- Federal Grant Award Summary The University of Florida received a $153,500 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective May 1, 2026, through April 30, 2028. The award supports research investigating thymic output in the context of genetics, environmental exposures, and progression to type 1 diabetes (T1D). The research addresses...
- Federal Grant Award Summary Florida State University received a $2.78M Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 1, 2025, through August 31, 2029. The award supports fundamental research to elucidate the molecular mechanisms by which pancreatic beta cells transition from adaptive responses to maladaptive dysfunction under...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded the University of Florida a Project Grant of $1,599,136 on August 18, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a precision medicine clinical trial addressing Type 1 Diabetes (T1D) treatment. The research will evaluate anti-thymocyte globulin (ATG), a T cell-specific immune therapy, with and without verapamil (a...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a Project Grant of $248,975.00 to The Regents of the University of Colorado-Denver under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) for research activities spanning from May 15, 2026, through April 30, 2029. The funded research investigates pancreatic beta-cell glucose toxicity and its relationship to messenger RNA (mRNA) translation, with...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Scripps Research Institute a $801,662 Project Grant effective August 15, 2025, through June 30, 2029, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research project investigates the initiation of anti-islet autoimmunity in Type 1 Diabetes (T1D), a CD4 T cell-mediated autoimmune disease, with particular focus on understanding the role...
- Federal Grant Award Summary The Beckman Research Institute of the City of Hope received a $153,554 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 15, 2025, with a completion date of July 31, 2030. The award funds research on alpha cell heterogeneity and its implications for Type 1 Diabetes (T1D) therapy development. The principal...
- Federal Grant Award Summary The Beckman Research Institute of the City of Hope received a $178,000 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective May 1, 2026, through April 30, 2028. The award funds research investigating how the native pancreatic microenvironment regulates human islet cell function in health and Type 1 Diabetes (T1D). The...
- Federal Project Grant Award Summary The Beckman Research Institute of the City of Hope received a $178,000 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective May 1, 2026 through April 30, 2028. This award supports fundamental and translational research focused on understanding stress response pathways in Type 1 Diabetes (T1D) through...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded the University of Virginia a $1.44 million Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) for the period May 1, 2026 through April 30, 2029. This ancillary research project will utilize data and peripheral blood mononuclear cell (PBMC) samples from the Environmental Determinants of Diabetes in the Young (TEDDY) longitudinal...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1.45 million Project Grant to Beckman Research Institute of the City of Hope, effective August 20, 2025, through June 30, 2030, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). This award funds fundamental and translational research investigating chromatin remodeling factors and mechanisms in diabetic microvascular complications. The...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded the University of Florida $754,682 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) beginning May 1, 2026, and continuing through April 30, 2030. This Project Grant funds research investigating beta cell impairment in Type 1 Diabetes (T1D) through analysis of glucose metabolism in human pancreatic tissue samples. The research deliverables include identification of dysfunctional bioenergetics in beta cells during early-stage T1D using live human pancreas tissue slices, spatial metabolomics mapping via MALDI imaging, and spatial proteomics analysis via Akoya Phenocycler technology. The project will also characterize the relationship between immune dysregulation and beta cell dysfunction using both human tissue samples and mouse disease models, employing novel tools such as fixable calcium indicators to assess islet function within the local immune microenvironment. The research team leverages complementary expertise in islet imaging and physiology, beta cell metabolism, T1D immunology, and spatial metabolomics to identify altered components in glucose sensing and insulin secretory pathways associated with disease progression. Findings are intended to yield translatable insights regarding beta cell dysfunction with therapeutic applications for individuals with established T1D and persons with pre-diabetes, addressing a critical gap in understanding the combined metabolic and immunological mechanisms underlying T1D pathogenesis.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $754.7k | 5/5/26 |